Omega Fund Management, LLC — 13F Holdings & Portfolio
CIK 1637359 · latest 13F-HR filed 2026-05-15
Omega Fund Management, LLC manages $163.1M in 13F-reported U.S. long-equity assets across 10 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are BCAX (29.16%), NUVB (21.25%), BBOT (18.05%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 0 new positions, exited 1, added to 1, and trimmed 9.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$163.1M
Long-equity book
10
Distinct positions
2026-03-31
Filed 2026-05-15
+0 / −1 / ↑1 / ↓9
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Trims
- Nuvation Bio Inc.-$37.7M -52.1%
- Beta Bionics Inc.-$26.9M -67.1%
- Kestra Med Technologies Ltd-$16.1M -44.1%
- BridgeBio Oncology Therapeutics Inc.-$11.7M -28.5%
- enGene Holdings Inc.-$1.9M -24.6%
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | Bicara Therapeutics Inc. | BCAX | 055477103 | $47.6M | 29.16% | 2,392,150 | SH |
| 2 | Nuvation Bio Inc. | NUVB | 67080N101 | $34.7M | 21.25% | 8,081,089 | SH |
| 3 | BridgeBio Oncology Therapeutics Inc. | BBOT | 107924102 | $29.4M | 18.05% | 3,289,661 | SH |
| 4 | Kestra Med Technologies Ltd | KMTS | G52441105 | $20.4M | 12.49% | 1,022,149 | SH |
| 5 | Beta Bionics Inc. | BBNX | 08659B102 | $13.2M | 8.08% | 1,316,183 | SH |
| 6 | enGene Holdings Inc. | ENGNW | 29286M105 | $6.0M | 3.66% | 876,357 | SH |
| 7 | Alumis Inc. | ALMS | 022307102 | $5.3M | 3.26% | 241,255 | SH |
| 8 | Sana Biotechnology, Inc. | SANA | 799566104 | $2.4M | 1.49% | 843,750 | SH |
| 9 | ImageneBio, Inc. | IMA | 45175G207 | $2.3M | 1.40% | 455,361 | SH |
| 10 | Replimune Group | REPL | 76029N106 | $1.9M | 1.17% | 248,672 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | $163.1M | 10 | 0001193125-26-225480 |
| 2025-12-31 | 2026-02-17 | $286.5M | 11 | 0001193125-26-053268 |
| 2025-09-30 | 2025-11-14 | $222.4M | 12 | 0001193125-25-281790 |